ReNeuron Group plc (LON:RENE – Get Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 3.38 ($0.04) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares traded.
ReNeuron Group Price Performance
The firm has a market cap of £1.93 million, a P/E ratio of -37.50 and a beta of 0.83. The company has a debt-to-equity ratio of 14.25, a current ratio of 1.51 and a quick ratio of 2.02. The stock’s 50-day simple moving average is GBX 3.38 and its two-hundred day simple moving average is GBX 3.38.
About ReNeuron Group
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Featured Stories
- Five stocks we like better than ReNeuron Group
- Technology Stocks Explained: Here’s What to Know About Tech
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What is the S&P 500 and How It is Distinct from Other Indexes
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
